New drug shows promise for slowing liver damage in rare genetic disease
NCT ID NCT05899673
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study looks at the long-term safety of a drug called fazirsiran for people with liver disease caused by alpha-1 antitrypsin deficiency. About 31 participants who were in earlier studies will receive fazirsiran every 3 months. Researchers will monitor side effects and check if the drug can slow liver scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Hospital Nélio Mendonça
Funchal, 9000-168, Portugal
-
Medical University of South Carolina - Hollings Cancer Center - PPDS
Charleston, South Carolina, 29425-8900, United States
-
Medizinische Universitat Wien (Medical University of Vienna)
Vienna, A-1090, Austria
-
Royal Infirmary of Edinburgh - PPDS
Edinburgh, EH16 4SA, United Kingdom
-
Stanford Medicine Outpatient Center
Redwood City, California, 94063, United States
-
UCSD Altman Clinical and Translational Research Institute
La Jolla, California, 92037-1337, United States
-
UF Clinical and Translational Science Institute
Gainesville, Florida, 32610-3010, United States
-
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, 52242-1009, United States
-
Universitätsklinikum der RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
Conditions
Explore the condition pages connected to this study.